A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Peer Review reports

Original Submission
22 Aug 2012	Submitted	Original manuscript
18 Nov 2012	Reviewed	Reviewer Report - Mark McKeage
14 Jan 2013	Reviewed	Reviewer Report - Peter Fong
19 Feb 2013	Author responded	Author comments - Iman El-Hariry
Resubmission - Version 2
19 Feb 2013	Submitted	Manuscript version 2
2 Mar 2013	Reviewed	Reviewer Report - Mark McKeage
2 Mar 2013	Reviewed	Reviewer Report - Peter Fong
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
19 Mar 2013	Editorially accepted
25 Mar 2013	Article published	10.1186/1471-2407-13-152

Back to article page